These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20726858)

  • 1. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
    Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
    Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.
    Zhu J; Siclari VA; Liu F; Spatz JM; Chandra A; Divieti Pajevic P; Qin L
    PLoS One; 2012; 7(12):e50099. PubMed ID: 23300521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
    El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.
    Rittié L; Kansra S; Stoll SW; Li Y; Gudjonsson JE; Shao Y; Michael LE; Fisher GJ; Johnson TM; Elder JT
    Am J Pathol; 2007 Jun; 170(6):2089-99. PubMed ID: 17525275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of HB-EGF and amphiregulin as targets for human cancer therapy.
    Yotsumoto F; Yagi H; Suzuki SO; Oki E; Tsujioka H; Hachisuga T; Sonoda K; Kawarabayashi T; Mekada E; Miyamoto S
    Biochem Biophys Res Commun; 2008 Jan; 365(3):555-61. PubMed ID: 18023415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
    Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
    MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
    Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
    Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
    Eckstein N; Servan K; Girard L; Cai D; von Jonquieres G; Jaehde U; Kassack MU; Gazdar AF; Minna JD; Royer HD
    J Biol Chem; 2008 Jan; 283(2):739-50. PubMed ID: 17942395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
    Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
    Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
    [No Abstract]   [Full Text] [Related]  

  • 16. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
    Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
    Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
    Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats.
    Cuevas MJ; Tieppo J; Marroni NP; Tuñón MJ; González-Gallego J
    J Nutr; 2011 Jul; 141(7):1299-305. PubMed ID: 21562239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.
    Zhou Y; Lee JY; Lee CM; Cho WK; Kang MJ; Koff JL; Yoon PO; Chae J; Park HO; Elias JA; Lee CG
    J Biol Chem; 2012 Dec; 287(50):41991-2000. PubMed ID: 23086930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.